Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures, which might be useful in the treatment of cancers, and vascular and metabolic diseases; and LB-200 series for the treatment of chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; pharmacologic study with the National Cancer Institute; and clinical research support agreement with City of Hope National Medical Center to carry out a Phase 1b clinical trial of its LB-100, a protein phosphatase inhibitor for small cell lung cancer. The company was incorporated in 2005 and is based in East Setauket, New York.
IPO Year:
Exchange: NASDAQ
Website: lixte.com
| Date | Price Target | Rating | Analyst |
|---|
S-1/A - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)
PRE 14A - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)
8-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)
S-1 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)
8-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)
8-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)
8-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)
8-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)
10-Q - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)
8-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)
4/A - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
3 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
SC 13G - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)
SC 13G/A - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)
SC 13G - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)
Patent Covers Combining LIXTE's LB-100 with Various Innovative Cancer Immunotherapies PASADENA, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) ("LIXTE" or the "Company") today announced it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent application number 16/467,721, titled, "Oxabicycloheptanes for Modulation of Immune Response," for combining the Company's LB-100 compound with various innovative cancer immunotherapies. "The patent award further bolsters LIXTE's existing intellectual property portfolio and underscores the Company's commitment to pioneering research and delivering in
PASADENA, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) ("LIXTE" or the "Company"), today announced the dosing of the first patient in a new clinical trial in collaboration with the Netherlands Cancer Institute (NKI) and supported by F. Hoffmann-La Roche Ltd. ("Roche") for treatment of unresponsive (MSI Low) metastatic colorectal cancer. As part of the clinical trial (NCT06012734, clinicaltrials.gov), LIXTE is providing its lead compound, LB-100, and Roche is providing atezolizumab (Tecentriq ®, a PDL1 inhibitor) through the imCORE Network, a global academic-industry partnership that aims to accelerate cancer immunotherapy research through inst
-Collaboration with NKI and Funding Support for New Colorectal Cancer Clinical Trial by Major Pharma Company- -Distinguished Oncologist Jan Schellens Joins LIXTE as Chief Medical Officer- -Preclinical Data Published in Journal EMBO Reports Shows LB-100 as Potentially Enhancing the Benefit of Immunotherapy- -LIXTE to Present at Two Upcoming Investor Conferences- PASADENA, CA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on the Company's recent activities. "We are
-Company to Present August 20 at Investor Summit Summer 2024 Virtual Conference; and September 9-11 at H.C. Wainwright 26th Annual Global Investment Conference- PASADENA, CALIF., Aug. 15, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical company, today announced it will be presenting at two investor conferences: The Investor Summit Summer 2024 Virtual Conference Tuesday, August 20, 2024, at 2 p.m. EDT/11 a.m. PDT. To access the presentation, visit LIXTE's investor relations website at https://ir.lixte.com/news-events/ir-calendar.The H.C. Wainwright 26th Annual Global Investor Conference, on demand
NEW YORK, NY / ACCESSWIRE / August 14, 2024 / Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.Event: Q3 Investor SummitDate: August 20th, 2024Presentation Time: 2:00 pm ETLocation: https://www.webcaster4.com/Webcast/Page/3062/51117The theme is 50 micro-cap companies with a catalyst and/or strong performance in the current market.Take a deep dive with the best Investors in MicroCapLive Q & AComplimentary to Qualified Investors. Please REGISTER HE
Clinical trial to test recent findings that show LIXTE's lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical company, today announced a collaboration with Roche and the Netherlands Cancer Institute (NKI) to conduct a new clinical trial in immune therapy unresponsive (MSI Low) metastatic colon cancer. As part of the new clinical trial, listed as NCT06012734 at clinicaltrials.gov, LIXTE will provide its lead compound, LB-100, and Roche will provide atezolizumab (Tecentriq®, a PD-L1 inhibito
Clinical trial to test recent findings that show LIXTE's lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical company, today announced a collaboration with Roche and the Netherlands Cancer Institute (NKI) to conduct a new clinical trial in immune therapy unresponsive (MSI Low) metastatic colon cancer. As part of the new clinical trial, listed as NCT06012734 at clinicaltrials.gov, LIXTE will provide its lead compound, LB-100, and Roche will provide atezolizumab (a PD-L1 inhibitor) and financ
LB-100 Generates Neo-Antigens in Cancer Cells that are Presented to the Immune System by Disrupting the Process of RNA Splicing PASADENA, CA, June 06, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical company, today announced online publication of new pre-clinical data in the journal EMBO Reports, showing that its lead compound, LB-100, can turn immunologically "cold" tumors "hot," potentially enhancing the benefit of immunotherapy. In a paper titled, "The Phosphatase Inhibitor LB-100 Creates Neoantigens in Colon Cancer Cells through Perturbation of mRNA Splicing," LIXTE's collaborators from the Nethe
PASADENA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today announced the appointment of Jan Schellens, M.D., Ph.D., as Chief Medical Officer (CMO). Dr. Schellens brings to LIXTE more than 25 years of clinical experience as a medical oncologist, pharmacologist and clinical pharmacologist, including more than two decades developing and bringing new drugs to market. He assumes the CMO role at LIXTE effective August 1, 2024, succeeding James S. Miser, M.D., who is leaving the Company after serv
Publishing of Findings in Recent Pre-Clinical Study for LIXTE's Proprietary Compound, LB-100, in New Field of Cancer Biology, "Activation Lethality"Presentation at MedInvest Biotech and Pharma Investor ConferenceCo-Sponsorship/Presentation of Workshop at Harvard University's Dana Farber Cancer Institute PASADENA, CA, May 20, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on the Company's recent activities, including notable pre-clinical developments. "LIXTE continues to make
PASADENA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today announced the appointment of Jan Schellens, M.D., Ph.D., as Chief Medical Officer (CMO). Dr. Schellens brings to LIXTE more than 25 years of clinical experience as a medical oncologist, pharmacologist and clinical pharmacologist, including more than two decades developing and bringing new drugs to market. He assumes the CMO role at LIXTE effective August 1, 2024, succeeding James S. Miser, M.D., who is leaving the Company after serv
Biotechnology Veteran Bas van der Baan Brings Precision Oncology Expertise; Founder John S. Kovach Named Executive Chairman PASADENA, CA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A inhibitors, announced that Bas van der Baan has been named as President and Chief Executive Officer of the Company, and as Vice Chairman of the Board of Directors, effective as of September 26, 2023. He has been a member of LIXTE'S Board of Directors since June 2022. Mr. van der Baan succeeds John S. Kovach, M.D., 87, who founded the Company in 2005 a
PASADENA, CA, June 21, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, announced the appointment of Bas van der Baan to its Board of Directors. He will serve as an independent director. Dr. John S. Kovach, Founder and Chief Executive Officer of Lixte, commented, "We are very pleased to welcome Mr. van der Baan to our Board of Directors. Mr. van der Baan has over 20 years of experience in the biotechnology industry with a key focus on oncology and diagnostics. He has extensive knowhow in the journey from clinical development to reimbursement and commercialization
Bernards is internationally recognized for his contributions to the development of effective anti-cancer drugs from their earliest stages through clinical use PASADENA, CA, June 15, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, announced the appointment of Professor René Bernards to its Board of Directors. Professor Bernards will serve as an independent director. Dr. John S. Kovach, Founder and Chief Executive Officer of Lixte, commented, "We are very pleased to welcome Professor Bernards to our Board of Directors and we look forward to his insight and
EAST SETAUKET, New York, April 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. ("Lixte" or the "Company") (NASDAQ:LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, announced the appointment of Gil N Schwartzberg to its Board of Directors. Mr. Schwartzberg is filling a vacancy created by the resignation of Winson (Sze Chun) Ho, M.D. Dr. John S. Kovach, the Founder and Chief Executive Officer of Lixte, commented, "Gil Schwartzberg has played an important role advising and supporting Lixte since its inception. We are pleased to be welcoming Mr. Schwartzberg to our Board of Directors." Dr. Kovach continue
LB-100 Generates Neo-Antigens in Cancer Cells that are Presented to the Immune Systemby Disrupting the Process of RNA Splicing
https://register.epo.org/application?number=EP20167812
Gainers Akso Health Group (NASDAQ:AHG) shares rose 11.4% to $0.79 during Friday's after-market session. The company's market cap stands at $116.0 million. China SXT Pharmaceuticals (NASDAQ:SXTC) shares increased by 10.43% to $1.27. The company's market cap stands at $1.1 million. CareCloud (NASDAQ:CCLD) stock increased by 10.07% to $2.84. The company's market cap stands at $45.7 million. The company's, Q1 earnings came out 3 days ago. Eledon Pharma (NASDAQ:ELDN) shares moved upwards by 9.63% to $3.31. The company's market cap stands at $125.5 million. OneMedNet (NASDAQ:ONMD) shares increased by 7.52% to $0.5. The market value of their outstanding shares is at $11.9 million. Reshape Lif
-SEC Filing
White Diamond on X: "BREAKING NEWS: Lixte Biotechnology Lied: Its Publication Yesterday Isn't New – It's The Same One They Published Over A Year Ago $LIXT See news brief here: https://t.co/J4o4XA38nK" / X (twitter.com) whitediamondresearch.com/archive/lixte-biotechnology-publication-yesterday-is-the-same-one-published-over-a-year-ago/
U.S. stocks traded mostly higher toward the end of trading, with the Dow Jones index gaining over 300 points on Wednesday. The Dow traded up 0.78% to 39,589.55 while the NASDAQ fell 0.02% to 16,312.74. The S&P 500 also rose, gaining, 0.36% to 5,222.18. Check This Out: Top 3 Energy Stocks That May Keep You Up At Night In Q1 Leading and Lagging Sectors Utilities shares jumped by 2% on Wednesday. In trading on Wednesday, communication services shares fell by 0.5%. Top Headline Cintas Corporation (NASDAQ:CTAS) reported better-than-expected third-quarter financial results and raised FY24 guidance. Cintas posted GAAP earnings of $3.84 per share, beating market estimates of $3
Shares of LuxUrban Hotels Inc. (NASDAQ:LUXH) fell sharply during Wednesday’s session after the company issued preliminary fourth-quarter revenue outlook below estimates. LuxUrban said it expects preliminary revenue of $28.2 million for the fourth quarter, versus market estimates of $34.199 million, according to data from Benzinga Pro. LuxUrban Hotels shares dipped 27.4% to $1.5523 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers MariaDB plc (NYSE:MRDB) climbed 70.4% to $0.3850 after Progress Software announced that it is possibly considering an offer for the company. Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) shares jumped 68.6% to $3.8099
Gainers Stoke Therapeutics (NASDAQ:STOK) shares increased by 46.1% to $15.03 during Wednesday's regular session. The company's market cap stands at $671.1 million. As per the press release, Q4 earnings came out 2 days ago. Lixte Biotechnology (NASDAQ:LIXT) shares rose 43.68% to $3.24. The company's market cap stands at $7.2 million. Nuvation Bio (NYSE:NUVB) shares moved upwards by 35.41% to $3.9. The company's market cap stands at $854.2 million. Ontrak (NASDAQ:OTRK) shares moved upwards by 29.18% to $0.55. The market value of their outstanding shares is at $15.2 million. PAVmed (NASDAQ:PAVM) stock increased by 25.72% to $2.59. The market value of their outstanding shares is at $20.8 mi